What is it about?
Up to now, although there are many AR antagonists on the market, drug resistance develops after prolonged usage. Based on our previous work, we designed and synthesized a series of novel pyrazole-5-carboxamide derivatives. Here, these promising data supported a further evaluation of compound 24 as a potential candidate to treat prostate cancer.
Photo by National Cancer Institute on Unsplash
Why is it important?
Prostate cancer (PCa) is the most common malignant tumor in the male genitourinary system.The representative drugs have achieved valuable clinical success, including flutamide and bicalutamide, but these antagonists develop resistance inevitably after prolonged usage. As a result, it is urgent to search for novel AR antagonists to treat prostate cancer.
Read the Original
This page is a summary of: Design, Synthesis and Biological Evaluation of 1-methyl-1H-pyrazole-5-Carboxamide Derivatives as Novel Anti-Prostate Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry, November 2021, Bentham Science Publishers, DOI: 10.2174/1871520621666210202162953.
You can read the full text:
The following have contributed to this page